21
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          1 In a recent issue of Br J Clin Pharmacol, Smith et al. 1 published an outstanding commentary titled “Dosing will be a key success factor in repurposing antivirals for Covid‐19.” They highlighted that the success in our repurposing efforts will be dependent on “getting the dose right” for drugs which have been developed for different indications and stressed some of the unique challenges of treating this particular disease. They pointed the reader to lopinavir/ritonavir (LPV/r) as an example of a repurposed antiviral and the limited experience of this drug regimen (and other treatments) in the elderly population with comorbidities—that is, those most at risk from Covid‐19. It is on the issue of comorbidities, polypharmacy, and drug‐drug interactions (DDIs) that we wish to comment. Age‐related comorbidities result in complex polypharmacy and an increased risk of DDIs. 2 Furthermore, physiological changes related to ageing may affect both pharmacokinetics (PK) and pharmacodynamics (PD) thereby putting elderly patients at risk of inappropriate prescribing and adverse drug reactions. In the case of LPV/r, particular attention needs to be focussed on PK interactions involving inhibition of CYP3A4 and some transporters. 2 To aid health care professionals managing LPV/r (and other antiretroviral) DDIs in HIV patients, we developed the online resource http://www.hiv-druginteractions.org, 3 which is extensively cited in national and international treatment guidelines. However, in addition to PK interactions, LPV/r is known to cause QT prolongation and is on the CredibleMeds listing 4 for drugs with a possible risk of torsades de pointes (TdP). Indeed, the drug label for LPV/r includes the warning to “avoid use with QT‐prolonging drugs” because of DDIs and effects on PR and QTc. 5 Possibly of greater topicality at present is the risk of QT prolongation and TdP in Covid‐19 patients given the repurposed drugs chloroquine and hydroxychloroquine. This has been highlighted in recent cohort studies 6 , 7 and in warnings from the EMEA 8 and FDA. 9 Patients given experimental COVID‐19 therapies will often be clinically unstable with organ dysfunction, and the development of toxicities from DDIs must be carefully considered. These very ill patients may not only be receiving an experimental COVID drug with a known or possible risk of TdP as single agents or combined (LPV/r, chloroquine, hydroxychloroquine, and azithromycin) 4 but can have other risk factors for TdP such as hypokalaemia, female gender, age > 70 years, and concomitant (e.g., some anaesthetics, muscle relaxants, analgesics, antiarrhythmics, antibacterials, antipsychotics, and gastrointestinal agents) thereby potentially increasing the risk of TdP. 10 The CredibleMeds website classifies drugs into those with a known risk, a possible risk, and a conditional risk of TdP. However, there is still the challenge of giving appropriate clinical advice to guide the safe use of a COVID therapy and one or more co‐medications in individual patients. Having established prescribing resources for managing DDIs in other viral infections (with a database of commentaries on >30 000 DDIs, with data systematically collected from medical and scientific literature, information from drug regulatory authorities or expert opinion), to meet the challenge of the COVID pandemic a similar resource is now available at http://www.covid19-druginteractions.org. 11 DDIs are graded into four levels and colour coded: (i) no clinically significant interaction expected (green); (ii) potential interaction likely of weak relevance (yellow); (iii) potential interaction that may require close monitoring, alteration of drug dosage or timing of administration (amber); and (iv) drugs should not be co‐administered (red). It is made clear that the decision to give or not give drugs is always the responsibility of the prescriber with many other factors having to be considered such as age and electrolyte imbalance. In addition, since chloroquine and hydroxychloroquine have very long half‐lives (30–60 days), DDIs may occur even after discontinuing treatment. 9 Systematic medication review should aim at discontinuing unnecessary QT prolonging drugs or finding alternatives devoid of QT risk. The use of decision support systems is important in effective management of drug therapies in COVID patients. 2 COMPETING INTERESTS D.Ba. and S.K. received educational grant funding for http://www.covid19-druginteractions.org from Novartis and Abbvie. CONTRIBUTORS D.Ba., C.M., C.H., F.M., A.B., S.G., D.Bu., and S.K. have all been involved in the development of the web resource http://www.covid19-druginteractions.org. D.Ba., C.M., and D.Bu. wrote this manuscript.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: not found
          • Article: not found

          The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The challenge of HIV treatment in an era of polypharmacy

            Abstract Introduction The availability of potent antiretroviral therapy has transformed HIV infection into a chronic disease such that people living with HIV (PLWH) have a near normal life expectancy. However, there are continuing challenges in managing HIV infection, particularly in older patients, who often experience age‐related comorbidities resulting in complex polypharmacy and an increased risk for drug‐drug interactions. Furthermore, age‐related physiological changes may affect the pharmacokinetics and pharmacodynamics of both antiretrovirals and comedications thereby predisposing elderly to adverse drug reactions. This review provides an overview of the therapeutic challenges when treating elderly PLWH (i.e. >65 years). Particular emphasis is placed on drug‐drug interactions and other common prescribing issues (i.e. inappropriate drug use, prescribing cascade, drug‐disease interaction) encountered in elderly PLWH. Discussion Prescribing issues are common in elderly PLWH due to the presence of age‐related comorbidities, organ dysfunction and physiological changes leading to a higher risk for drug‐drug interactions, drugs dosage errors and inappropriate drug use. Conclusions The high prevalence of prescribing issues in elderly PLWH highlights the need for ongoing education on prescribing principles and the optimal management of individual patients. The knowledge of adverse health outcomes associated with polypharmacy and inappropriate prescribing should ensure that there are interventions to prevent harm including medication reconciliation, medication review and medication prioritization according to the risks/benefits for each patient.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Dosing will be a key success factor in repurposing antivirals for COVID‐19

                Bookmark

                Author and article information

                Contributors
                daveback@liverpool.ac.uk
                Journal
                Br J Clin Pharmacol
                Br J Clin Pharmacol
                10.1111/(ISSN)1365-2125
                BCP
                British Journal of Clinical Pharmacology
                John Wiley and Sons Inc. (Hoboken )
                0306-5251
                1365-2125
                13 May 2020
                : 10.1111/bcp.14358
                Affiliations
                [ 1 ] Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine University of Liverpool Liverpool UK
                [ 2 ] Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research University Hospital of Basel Basel Switzerland
                [ 3 ] University of Basel Basel Switzerland
                [ 4 ] Department of Pharmacy NHS Greater Glasgow and Clyde Glasgow UK
                [ 5 ] Radboud University Medical Centre Nijmegen The Netherlands
                [ 6 ] Royal Liverpool University Hospital Liverpool UK
                Author notes
                [*] [* ] Correspondence

                David Back, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

                Email: daveback@ 123456liverpool.ac.uk

                Author information
                https://orcid.org/0000-0002-7381-4799
                https://orcid.org/0000-0001-7279-2818
                Article
                BCP14358 LET-00408-20
                10.1111/bcp.14358
                7267419
                32384171
                ba3d8477-8a4e-410e-a037-65ccd1fd9c12
                © 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 29 April 2020
                : 04 May 2020
                Page count
                Figures: 0, Tables: 0, Pages: 2, Words: 1032
                Funding
                Funded by: Abbvie , open-funder-registry 10.13039/100006483;
                Funded by: Novartis , open-funder-registry 10.13039/100004336;
                Categories
                Letter to the Editor
                Letter to the Editor
                Custom metadata
                2.0
                corrected-proof
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:03.06.2020

                Pharmacology & Pharmaceutical medicine
                Pharmacology & Pharmaceutical medicine

                Comments

                Comment on this article